METHODS: This study employed a quantitative design, disseminating surveys via Sina Weibo and the Douyin platform. We collected a total of 525 valid responses. This study aims to deeply explore the social and psychological factors generated by digital religious activities on social media platforms, particularly how they stimulate Chinese Generation Z youth to participate in digital religious activities.
RESULTS: The results show that attitudes toward digital religion, perceived behavioral control, social identity, and empathetic willingness are predictors of intentions, while social norms are not. Intentions significantly predict users'behavior on social media platforms such as Weibo and Douyin. Moreover, empathetic willingness and social identity fully mediate the effects of subjective norms, perceived behavioral control, and attitudes on intentions. Consequently, these behaviors generate impact, indicating the presence of multiple mediation effects.
DISCUSSION: Unlike the societal context of theistic nations, there is a pronounced atheistic inclination within Chinese society. Consequently, subjective norms do not influence the digital religious behaviors of Chinese youth. Among contemporary Chinese youth, participation in digital religious practices is a temporary, secular activity undertaken only as a comforting behavior when anxiety becomes unmanageable or surpasses their threshold of tolerance. In contemporary China, young people face immense pressures stemming from workplace competition, social interactions, and economic burdens. Social media offers these young individuals broader opportunities for connection, community formation, and identity construction, as well as various possibilities for organizing their social lives. Consequently, on one hand, they turn to online religious avenues, seeking understanding from others through shared experiences, thereby obtaining emotional solace and comfort. On the other hand, they look to spiritual beliefs to alleviate anxiety, resolve confusion, and gain psychological comfort through emotional exchanges. Therefore, digital religion can, to some extent, be viewed as a form of social-technological empowerment, providing contemporary youth with a new "pressure valve" to facilitate emotional relief, comfort, and tension alleviation.
RESULTS: Target-site EPSPS gene sequencing revealed two partial sequences of the EPSPS transcripts (1001 bp and 998 bp), and the full-length sequence (1551 bp) containing the 1001-bp transcript was cloned as it was found in the resistant plants. A known resistance-endowing target-site mutation in the 1551-bp transcript was identified in the resistant plants, resulting in the Pro-106-Ser substitution. The subpopulation derived from these mutant plants exhibited >10-fold resistance to glyphosate compared to the susceptible population. Additionally, the EPSPS gene (1551 bp) was constitutively expressed at a higher level (4.3-fold) in the resistant than in the susceptible populations. However, 14C-glyphosate foliar uptake was similar with no visual difference in 14C-glyphosate translocation from leaves to other parts of a plant, between the resistant and susceptible population.
CONCLUSION: Glyphosate resistance in the studied population is associated with both a target-site mutation (Pro-106-Ser) and increased EPSPS gene expression. © 2025 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
METHODS: The ASSERT study was a phase 3, double-blind, randomised, placebo-controlled trial that enrolled patients at 21 medical centres or hospitals in ten countries (Belgium, France, Germany, Italy, Malaysia, the Netherlands, Poland, Türkiye, the UK, and the USA). Eligible patients had a genetically confirmed diagnosis of Alagille syndrome, a history of significant pruritus, and elevated serum bile acids. Patients were randomly assigned (2:1) to receive oral odevixibat 120 μg/kg per day or placebo for 24 weeks (in a block size of six and stratified by age: <10 years and ≥10 years to <18 years) via a web-based system. Patients, clinicians, study staff, and people analysing the data were masked to treatment allocation. The primary efficacy endpoint was change in caregiver-reported scratching score (on the PRUCISION instrument; range 0-4) from baseline to weeks 21-24. The prespecified key secondary efficacy endpoint was change in serum bile acid concentration from baseline to the average of weeks 20 and 24. Outcomes were analysed in patients who received at least one dose of study drug (the full analysis set for efficacy outcomes and the safety analysis set for safety outcomes). This trial is registered on ClinicalTrials.gov (NCT04674761) and EudraCT (2020-004011-28), and is completed.
FINDINGS: Between Feb 26, 2021, and Sept 9, 2022, 52 patients were randomly assigned to receive odevixibat (n=35) or placebo (n=17), all of whom were included in the analysis sets. The median age was 5·5 years (IQR 3·2 to 8·9). 27 (52%) of 52 patients were male and 25 (48%) were female. The mean scratching score was elevated at baseline in both groups (2·8 [SD 0·5] for odevixibat vs 3·0 [0·6] for placebo). Mean scratching scores at weeks 21-24 were 1·1 (0·9) for odevixibat and 2·2 (1·0) for placebo, representing a least-squares (LS) mean change of -1·7 (95% CI -2·0 to -1·3) for odevixibat and -0·8 (-1·3 to -0·3) for placebo, which was significantly greater for odevixibat than for placebo (difference in LS mean change from baseline -0·9 [95% CI -1·4 to -0·3]; p=0·0024). Odevixibat also resulted in significantly greater reductions in mean serum bile acids from baseline versus placebo (237 μmol/L [SD 115] with odevixibat vs 246 μmol/L [121] with placebo) to the average of weeks 20 and 24 (149 μmol/L [102] vs 271 μmol/L [167]; LS mean change -90 μmol/L [95% CI -133 to -48] with odevixibat vs 22 μmol/L [-35 to 80] with placebo; difference in LS mean change -113 μmol/L [95% CI -179 to -47]; p=0·0012). The most common treatment-emergent adverse events were diarrhoea (ten [29%] of 35 patients in the odevixibat group vs one [6%] of 17 in the placebo group) and pyrexia (eight [23%] vs four [24%]). Seven patients had serious treatment-emergent adverse events during the treatment period: five (14%) in the odevixibat group and two (12%) in the placebo group. No patients discontinued treatment and there were no deaths.
INTERPRETATION: Odevixibat could be an efficacious non-surgical intervention to improve pruritus, reduce serum bile acids, and enhance the standard of care in patients with Alagille syndrome. Longer-term safety and efficacy data of odevixibat in this population are awaited from the ongoing, open-label ASSERT-EXT study.
FUNDING: Albireo Pharma, an Ipsen company.